Do Appetite Suppressants Work? What NIDDK Reports
Medically reviewed by Medical Advisory Board Last reviewed 2026-05-13
Prescription weight-management medications combined with lifestyle changes add 3% to 12% average weight reduction after one year in federal trial data
National Institute of Diabetes and Digestive and Kidney Diseases clinical records report that approved prescription weight-management medicines combined with lifestyle changes produce on average 3% to 12% more weight loss after one year than lifestyle changes alone. Individual outcomes vary, and certain therapies help more than half of participants lose 10% or more of their body weight. A health care professional determines whether prescription treatment is appropriate.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), prescription weight-management medicines taken with lifestyle changes produce on average 3% to 12% more weight loss after one year than lifestyle changes alone. These Food and Drug Administration (FDA) approved weight loss drugs function through distinct biological mechanisms, including nutrient absorption, satiety signaling, and hormone regulation. Response rates vary among individuals, and a health care professional decides whether a medicine fits a patient.
Clinical findings documented by the NIDDK show that a weight reduction of 5% to 10% is linked to health benefits. With some prescription therapies, more than half of study participants lost 10% or more of their body weight over a one-year period. Evaluating whether prescription appetite suppressants work requires reviewing clinical trial outcomes, mechanisms of action, and health exclusions for each approved medication.
Partner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →How Much Weight Loss Medicines Add
Prescription weight-management medicines combined with lifestyle changes produce on average 3% to 12% more body weight loss after one year than lifestyle changes alone. The NIDDK reports that adding an approved medication to lifestyle modifications leads to greater average weight reduction than non-medical approaches alone. Response rates differ across individuals, meaning that measured outcomes vary from patient to patient.
Across clinical trials evaluated by the NIDDK, more than half of participants taking certain medications lost 10% or more of their body weight after one year. In addition, research records confirm that losing 5% to 10% of total body weight is linked to health benefits. A health care professional evaluates individual health factors to decide if a patient is a candidate for prescription treatment.
Medicines That Act on Absorption
Orlistat is an approved weight-management medication that works in the gut to reduce the amount of fat absorbed from food. Marketed under the brand names Xenical and Alli, orlistat functions locally in the digestive system rather than altering brain pathways that control hunger. Patients take orlistat as a pill three times daily.
Orlistat is approved for adults and children aged 12 and older. The NIDDK lists problems absorbing nutrients and cholestasis among the conditions for which the medicine is not suited.
Medicines That Act on Appetite and Fullness in the Brain
Several oral and injectable medications work directly in the brain to decrease appetite and promote fullness. Phentermine-topiramate, sold under the brand name Qsymia, combines two medications into a once-daily pill approved for adults and children aged 12 and older. This combination reduces appetite and promotes fullness.
Naltrexone-bupropion, marketed as Contrave, is a combination therapy that decreases hunger and promotes fullness. Patients take naltrexone-bupropion as a pill one to two times daily. This medication is approved for adults only.
Setmelanotide, known by the brand name Imcivree, activates brain pathways to decrease appetite and food intake while increasing calories the body uses. Administered as a daily injection, setmelanotide is approved for adults and children aged 6 and older who have specific rare genetic disorders. The NIDDK lists these conditions as pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome.
Hormone-Mimicking Injections
Certain injectable weight-management medications mimic metabolic hormones to target brain areas regulating appetite and food intake. Liraglutide, marketed as Saxenda, mimics glucagon-like peptide-1 (GLP-1), a hormone that targets brain regions controlling hunger. Administered as a daily injection, liraglutide is approved for adults and children aged 12 and older.
Semaglutide, sold under the brand name Wegovy, also mimics GLP-1 and is administered as a weekly injection for adults and pediatric patients aged 12 and older. The NIDDK notes that some people taking semaglutide lose 10% or more of their body weight. Patients evaluating GLP-1 appetite treatments can review clinical data regarding Ozempic and weight loss, factors behind a GLP-1 plateau, and documented GLP-1 side effects.
Tirzepatide, marketed as Zepbound, mimics two hormones: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. By targeting brain areas that regulate appetite and food intake through both hormonal pathways, tirzepatide acts on both. Tirzepatide is administered as a weekly injection and is approved for adults only.
Who Each Medicine Is Not Suited For
NIDDK lists specific medical exclusions for every approved weight-management medication. The NIDDK lists specific health conditions for which each approved therapy is not suited.
| Medication | Delivery method | Approved age group | Conditions not suited for use |
|---|---|---|---|
| Orlistat (Xenical, Alli) | Pill three times daily | Adults and children 12+ | Problems absorbing nutrients, cholestasis |
| Phentermine-topiramate (Qsymia) | Pill once daily | Adults and children 12+ | Glaucoma, hyperthyroidism, MAOI use in the past 14 days |
| Naltrexone-bupropion (Contrave) | Pill 1 to 2 times daily | Adults only | Uncontrolled high blood pressure, seizures, anorexia, bulimia, recent MAOI use, frequent opioid use, taking other bupropion products, recent sudden stopping of alcohol, benzodiazepines, or barbiturates |
| Liraglutide (Saxenda) | Daily injection | Adults and children 12+ | Personal or family history of medullary thyroid cancer (MTC) or MEN 2 |
| Semaglutide (Wegovy) | Weekly injection | Adults and children 12+ | Personal or family history of medullary thyroid cancer (MTC) or MEN 2 |
| Tirzepatide (Zepbound) | Weekly injection | Adults only | Personal or family history of medullary thyroid cancer (MTC) or MEN 2 |
For phentermine-topiramate, the NIDDK lists glaucoma, hyperthyroidism, and monoamine oxidase inhibitor (MAOI) use in the past 14 days among the conditions for which the medicine is not suited. For naltrexone-bupropion, the NIDDK lists uncontrolled high blood pressure, seizures, anorexia, bulimia, recent MAOI use, frequent opioid use, other bupropion products, or recent sudden stopping of alcohol, benzodiazepines, or barbiturates. For liraglutide, semaglutide, and tirzepatide, the NIDDK lists a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) as conditions for which the medicines are not suited.
Questions for a Clinician
Decisions regarding prescription weight-management medications require consultation with a qualified clinician. Because individual medical histories, existing conditions, and concurrent therapies affect treatment appropriateness, selecting a therapy remains a clinical judgment.
Questions about these medicines can go to a clinician through the clinician consultation.
Frequently Asked Questions
Is there an appetite suppressant that actually works?
Approved prescription weight-management medicines produce on average 3% to 12% more body weight loss after one year compared to lifestyle changes alone, according to NIDDK clinical records. Clinical responses vary among individuals, with more than half of trial participants losing 10% or more of their body weight on certain medications. A health care professional determines whether a specific medicine is appropriate for an individual patient.
Which appetite suppressants are FDA approved?
The FDA has approved several prescription weight-management medications that reduce appetite, increase fullness, or decrease fat absorption. These medications include orlistat (Xenical, Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Zepbound), and setmelanotide (Imcivree). Each medication carries distinct administration schedules, age approvals, and clinical exclusions documented by the NIDDK.
Do GLP-1 medicines reduce appetite?
The NIDDK documents that GLP-1 medicines mimic glucagon-like peptide-1, a hormone that targets brain areas regulating appetite and food intake. Medications such as liraglutide and semaglutide utilize this mechanism to target brain regions involved in appetite regulation. In addition, tirzepatide mimics two hormones, GIP and GLP-1, targeting brain areas that regulate appetite and food intake.
Who should not take appetite suppressants?
The NIDDK lists specific health conditions for which each approved medication is not suited. NIDDK lists problems absorbing nutrients and cholestasis for orlistat, and glaucoma, hyperthyroidism or MAOI use in the past 14 days for phentermine-topiramate. For naltrexone-bupropion it lists uncontrolled high blood pressure, seizures, anorexia, bulimia, frequent opioid use, other bupropion products, or recent sudden stopping of alcohol, benzodiazepines, or barbiturates. For liraglutide, semaglutide and tirzepatide it lists a personal or family history of medullary thyroid cancer or MEN 2.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want weight loss handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Guides
-
Natural Appetite Suppressants
Natural appetite suppressants ranked by evidence quality, from glucomannan to garcinia cambogia, plus safety.